(A) Starting with naïve C57BL/6 mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content of the isolated fraction is typically 77.2 ± 2.4% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and isolated fractions are 0.6% and 77.6%, respectively. (B) Starting with immunized BALB/c mouse splenocytes, the plasma cell (CD138+CD267 (TACI)+) content of the isolated fraction is typically 86.1 ± 7.4% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and isolated fractions are 1.2% and 91.6%, respectively.
C) Starting with naïve C57BL/6 mouse bone marrow, the plasma cell (CD138+CD267 (TACI)+) content of the isolated fraction is typically 62.0 ± 13.1% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and isolated fractions are 0.3% and 71.1%, respectively. (D) Starting with immunized BALB/c mouse bone marrow, the plasma cell (CD138+CD267 (TACI)+) content of the isolated fraction is typically 85.5 ± 9.8% (mean ± SD using the purple EasySep™ Magnet). In the above example, the purities of the start and isolated fractions are 0.6% and 89.0%, respectively.
(E) Isolated CD138+ cells or total splenocytes from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antigen-specific hit rate was determined by ELISA. The % antigen-specific hit rates for total splenocytes and CD138+ cells were 3.2 ± 4.0% and 56.1 ± 37.2% (mean ± SD), respectively. (F) Isolated CD138+ cells or total bone marrow cells from mice immunized with various antigens were fused with Sp2/0 mouse myeloma cells and plated in semi-solid medium using ClonaCell™-HY Hybridoma Kit (Catalog #03800). The % antigen-specific hit rate was determined by ELISA. The % antigen-specific hit rates for total bone marrow cells and CD138+ cells were 0% and 31.9 ± 46.0% (mean ± SD), respectively.
This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.
Thank you for your interest in IntestiCult™ Organoid Growth Medium (Human). Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they
can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our
privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.
PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED. FOR ADDITIONAL INFORMATION ON QUALITY AT STEMCELL, REFER TO WWW.STEMCELL.COM/COMPLIANCE.
